Novo believes new CagriSema trial can hit weight loss goal

Novo Nordisk is building on its experience from an underwhelming December readout for obesity therapy CagriSema in a bid to hit its 25% weight loss goal in a new Phase III study set to begin this half.

During its 4Q24 results presentation, Novo Nordisk A/S (CSE:NOVO-B; NYSE:NVO) said the REDEFINE 11 trial will be longer and incorporate the potential for re-escalating dosing in patients who don’t reach the highest dose, as it seeks to demonstrate additional weight loss efficacy...